With new and unique technologies and active substances, the biotech company MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a focus on immuno-oncology, MOLOGEN also develops immunotherapies for the treatment of infectious diseases.
What sets us apart:
- Biotech company developing ground-breaking immunotherapies
- Lead product lefitolimod (MGN1703): potential blockbuster candidate
- Targeting indications with high unmet medical needs: Cancer and HIV
- Attractive for partnering/licensing: Advanced, close-to-market product candidate with long-term exclusivity and promising next generation successor molecules
- Clinically relevant subgroups benefit from the treatment with lefitolimod in this study - Results are indicative for the further development of lefitolimod in SCLC [more]